It was a quiet day for the Atlanta Braves on Tuesday which gave us a beat to think about where the Braves are right now with their roster.
One area that hasn’t really been addressed this offseason (other than the re-addition of Kolby Allard which probably doesn’t count) has been the rotation and that is with good reason. The Braves have four spots pretty well set going into 2023 and as Seth pointed out yesterday, they have enough candidates for the fifth spot in the rotation to at least entertain the idea of a six man rotation next season.
More Braves News
Elsewhere on the site, our prospect ranking rollout continued with prospects 11-15 and that installment had some interest. Included in that group is a former first round pick with some serious questions to answer as well as the position prospect that has some of the highest upside in the entire system.
Around the league, we had some signings of note. First, the Mets continued their reunion tour as they brought back Adam Ottavino on a two year deal worth $14.5 million. While Edwin Diaz got all of the attention out of the Mets’ bullpen last year, Ottavino was quite good as well (particularly against righties). Also, the Mets have committed nearly half a billion dollars this offseason and that is a lot of money….and they may not be done. Rumor has it that New York is considering making a move to trade for White Sox closer Liam Hendriks.
Matt Carpenter appeared to be on his way out of the league as age and injuries caught up with him over the last few seasons. He still struggled with injuries in 2022, but his amazing stat line when he WAS on the field earned him a one year deal with the Padres that includes a player option for 2024. He obviously won’t be able to sustain what he did over that 47 game sample in 2022 where he had a 217 wRC+, but maybe he can still be a useful lefty bat after all.
Finally, the huge deal that Carlos Correa signed with the Giants seems to have hit a bit of a snag. A report that came out yesterday indicated that Correa’s physical revealed a medical issue that was flagged and required additional testing. 13 years and $350 million is a lot of time and money, so the Giants should absolutely do their due diligence here…but thats a big oof if this deal doesn’t go through.